These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 31639831)

  • 1. A Thrombin-Activatable Factor X Variant Corrects Hemostasis in a Mouse Model for Hemophilia A.
    Muczynski V; Verhenne S; Casari C; Chérel G; Panicot-Dubois L; Gueguen P; Trossaert M; Dubois C; Lenting PJ; Denis CV; Christophe OD
    Thromb Haemost; 2019 Dec; 119(12):1981-1993. PubMed ID: 31639831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thrombin-activable factor X re-establishes an intrinsic amplification in tenase-deficient plasmas.
    Louvain-Quintard VB; Bianchini EP; Calmel-Tareau C; Tagzirt M; Le Bonniec BF
    J Biol Chem; 2005 Dec; 280(50):41352-9. PubMed ID: 16207719
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Next generation FIX muteins with FVIII-independent activity for alternative treatment of hemophilia A.
    Quade-Lyssy P; Abriss D; Milanov P; Ungerer C; Königs C; Seifried E; Schüttrumpf J
    J Thromb Haemost; 2014 Nov; 12(11):1861-73. PubMed ID: 25224783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved hemostasis in hemophilia mice by means of an engineered factor Va mutant.
    von Drygalski A; Cramer TJ; Bhat V; Griffin JH; Gale AJ; Mosnier LO
    J Thromb Haemost; 2014; 12(3):363-72. PubMed ID: 24818532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The mild phenotype in severe hemophilia A with Arg1781His mutation is associated with enhanced binding affinity of factor VIII for factor X.
    Yada K; Nogami K; Wakabayashi H; Fay PJ; Shima M
    Thromb Haemost; 2013 Jun; 109(6):1007-15. PubMed ID: 23467620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel therapeutic approach combining human plasma-derived Factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with Factor VIIa alone.
    Tomokiyo K; Nakatomi Y; Araki T; Teshima K; Nakano H; Nakagaki T; Miyamoto S; Funatsu A; Iwanaga S
    Vox Sang; 2003 Nov; 85(4):290-9. PubMed ID: 14633255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fitusiran reduces bleeding in factor X-deficient mice.
    Verhenne S; McCluskey G; Maynadié H; Adam F; Casari C; Panicot-Dubois L; Crescence L; Dubois C; Denis CV; Lenting PJ; Christophe OD
    Blood; 2024 Jul; 144(2):227-236. PubMed ID: 38620079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A factor VIIIa-mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice.
    Østergaard H; Lund J; Greisen PJ; Kjellev S; Henriksen A; Lorenzen N; Johansson E; Røder G; Rasch MG; Johnsen LB; Egebjerg T; Lund S; Rahbek-Nielsen H; Gandhi PS; Lamberth K; Loftager M; Andersen LM; Bonde AC; Stavenuiter F; Madsen DE; Li X; Holm TL; Ley CD; Thygesen P; Zhu H; Zhou R; Thorn K; Yang Z; Hermit MB; Bjelke JR; Hansen BG; Hilden I
    Blood; 2021 Oct; 138(14):1258-1268. PubMed ID: 34077951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene Delivery of Activated Factor VII Using Alternative Adeno-Associated Virus Serotype Improves Hemostasis in Hemophiliac Mice with FVIII Inhibitors and Adeno-Associated Virus Neutralizing Antibodies.
    Sun J; Hua B; Chen X; Samulski RJ; Li C
    Hum Gene Ther; 2017 Aug; 28(8):654-666. PubMed ID: 28478688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fibrin gel structure obtained with a FVIIa analogue with enhanced FX-activating potential in haemophilia.
    He S; Ezban M; Bark N; Persson E; Hedner U
    Thromb Haemost; 2009 Oct; 102(4):790-2. PubMed ID: 19806268
    [No Abstract]   [Full Text] [Related]  

  • 11. An antibody specific for coagulation factor IX enhances the activity of the intrinsic factor X-activating complex.
    Kerschbaumer RJ; Riedrich K; Kral M; Varadi K; Dorner F; Rosing J; Scheiflinger F
    J Biol Chem; 2004 Sep; 279(39):40445-50. PubMed ID: 15265864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A mutated factor X activatable by thrombin corrects bleedings in vivo in a rabbit model of antibody-induced hemophilia A.
    Abache T; Fontayne A; Grenier D; Jacque E; Longue A; Dezetter AS; Souilliart B; Chevreux G; Bataille D; Chtourou S; Plantier JL
    Haematologica; 2020 Sep; 105(9):2335-2340. PubMed ID: 33054058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contribution of Factor VIII A2 Domain Residues 400-409 to a Factor X-Interactive Site in the Factor Xase Complex.
    Takeyama M; Nogami K; Sasai K; Furukawa S; Shima M
    Thromb Haemost; 2018 May; 118(5):830-841. PubMed ID: 29614522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved coagulation and haemostasis in haemophilia with inhibitors by combinations of superFactor Va and Factor VIIa.
    Bhat V; von Drygalski A; Gale AJ; Griffin JH; Mosnier LO
    Thromb Haemost; 2016 Mar; 115(3):551-61. PubMed ID: 26466980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. General haemostatic agents--fact or fiction?
    Hedner U
    Pathophysiol Haemost Thromb; 2002; 32 Suppl 1():33-6. PubMed ID: 12214145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heterozygous antithrombin deficiency improves in vivo haemostasis in factor VIII-deficient mice.
    Bolliger D; Szlam F; Suzuki N; Matsushita T; Tanaka KA
    Thromb Haemost; 2010 Jun; 103(6):1233-8. PubMed ID: 20352163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combining FVIIa and FX into a mixture which imparts a unique thrombin generation potential to hemophilic plasma: an in vitro assessment of FVIIa/FX mixture as an alternative bypassing agent.
    Nakatomi Y; Nakashima T; Gokudan S; Miyazaki H; Tsuji M; Hanada-Dateki T; Araki T; Tomokiyo K; Hamamoto T; Ogata Y
    Thromb Res; 2010 May; 125(5):457-63. PubMed ID: 20080285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical efficacy and safety of rVIII-SingleChain (CSL627), a novel recombinant single-chain factor VIII.
    Zollner SB; Raquet E; Müller-Cohrs J; Metzner HJ; Weimer T; Pragst I; Dickneite G; Schulte S
    Thromb Res; 2013 Aug; 132(2):280-7. PubMed ID: 23830969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Intracranial hemorrhage and hemostasis. Monitoring patients after intracranial hemorrhage by determination and follow-up of activation products of blood coagulation].
    Menges T; von Lessen A; Welters I; Wagner RM; Ruwoldt R; Boldt J; Hempelmann G
    Infusionsther Transfusionsmed; 1994 Aug; 21(4):244-50. PubMed ID: 7950289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New insights into the coagulation system and implications for new therapeutic options with recombinant factor VIIa.
    Veldman A; Hoffman M; Ehrenforth S
    Curr Med Chem; 2003 May; 10(10):797-811. PubMed ID: 12678684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.